DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H2 2016" drug pipelines to their offering.
This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Diabetic Neuropathic Pain Overview
- Therapeutics Development
- Pipeline Products for Diabetic Neuropathic Pain - Overview
- Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis
- Diabetic Neuropathic Pain - Therapeutics under Development by Companies
- Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
- Diabetic Neuropathic Pain Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Diabetic Neuropathic Pain - Products under Development by Companies
- Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes
- Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development (Psrtial List)
- APT Therapeutics, Inc.
- Astellas Pharma Inc.
- BioDelivery Sciences International, Inc.
- Bristol-Myers Squibb Company
- Centrexion Therapeutics Corp
- Chromocell Corporation
- Daiichi Sankyo Company, Limited
- Grunenthal GmbH
- Hydra Biosciences, Inc.
For more information about this drug pipelines visit http://www.researchandmarkets.com/research/g35gtz/diabetic